These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3364505)

  • 1. Evaluation of the B-protein assay in cancer management.
    McGehee RP; Bucovaz ET; Whybrew WD; Griffis KR; Cothern D; Schweikert A; Morrison JC
    Am J Obstet Gynecol; 1988 Apr; 158(4):960-3. PubMed ID: 3364505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical value of tissue polypeptide antigen in patients with gynecologic tumors.
    Inoue M; Inoue Y; Hiramatsu K; Ueda G
    Cancer; 1985 Jun; 55(11):2618-23. PubMed ID: 3995474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The serum copper/serum iron ratio in malignant tumors of the female genitalia].
    Maas DH; Hinckers HJ
    Geburtshilfe Frauenheilkd; 1975 Aug; 35(8):619-26. PubMed ID: 1175904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. alpha-Fetoprotein as a biochemical marker in patients with gynecologic malignancy.
    Donaldson ES; van Nagell JR; Gay EC; Purcell S; Meeker WR; Kashmiri R; Hunter L; van de Voorde J
    Gynecol Oncol; 1979 Feb; 7(1):18-24. PubMed ID: 86481
    [No Abstract]   [Full Text] [Related]  

  • 5. Combating postmenopausal gynecologic malignancy.
    Rosenshein NB; Rotmensch J
    Geriatrics; 1982 May; 37(5):107-10, 115-6. PubMed ID: 7067979
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum immunosuppressive substance in patients with gynecologic malignancies and in pregnant women.
    Yamashita K; Hayashi H; Mure K; Ishikawa M; Shimizu T
    Cancer; 1986 Jan; 57(1):69-74. PubMed ID: 3940624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure patterns in gynecologic cancer.
    Brady LW; Perez CA; Bedwinek JM
    Int J Radiat Oncol Biol Phys; 1986 Apr; 12(4):549-57. PubMed ID: 3700163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between blood rheology, thrombosis and cancer survival in patients with gynecologic malignancy.
    von Tempelhoff GF; Nieman F; Heilmann L; Hommel G
    Clin Hemorheol Microcirc; 2000; 22(2):107-30. PubMed ID: 10831062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of patients with gynecologic cancer by serum sialic acid determination.
    Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
    Gynecol Oncol; 1989 May; 33(2):231-6. PubMed ID: 2703183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen.
    Inaba N; Negishi Y; Fukasawa I; Okajima Y; Ota Y; Tanaka K; Matsui H; Iwasaki H; Sudo H; Tanaka N
    Tumour Biol; 1995; 16(6):345-52. PubMed ID: 7569681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of N-acetylneuraminic acid (NANA) in the serum of patients with gynecologic cancers].
    Schrempel A; Kürschner M
    Zentralbl Gynakol; 1985; 107(3):175-8. PubMed ID: 3984572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of sialyl Tn antigen in patients with gynecologic tumors.
    Inoue M; Ogawa H; Nakanishi K; Tanizawa O; Karino K; Endo J
    Obstet Gynecol; 1990 Jun; 75(6):1032-6. PubMed ID: 2342728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum ferritin levels in patient with gynecological malignancy--especially the judgement of therapeutic response and the monitor during the post-therapeutic follow-up period (author's transl)].
    Washizuka N; Yamazaki T; Shimizu T; Kikuchi Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1981 Oct; 33(10):1695-702. PubMed ID: 7310197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary gonadotropin fragments (UGF) in cancers of the female reproductive system. II. Initial serial studies.
    Wang YX; Schwartz PE; Chambers JT; Cole LA
    Gynecol Oncol; 1988 Sep; 31(1):91-102. PubMed ID: 3410359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Human and medical aspects of treatment of recurrent gynecologic cancer].
    Revaz C
    Rev Med Suisse Romande; 1969 Jun; 89(6):679-95. PubMed ID: 5398848
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of circulating tumor necrosis factor-alpha in patients with gynecological malignancies.
    De Jaco P; Asselain B; Orlandi C; Fridman WH; Teillaud JL
    Int J Cancer; 1991 May; 48(3):375-8. PubMed ID: 2040531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gynecologic tumor].
    Kimura I; Togashi K; Konishi J; Taii S; Takai I; Mori T; Tamai T
    Gan To Kagaku Ryoho; 1990 Nov; 17(11):2172-81. PubMed ID: 2241181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tissue polypeptide antigen as a tumor marker for gynecologic malignancies].
    Inoue M; Fujita Y; Abe Y; Inoue Y; Ueda G; Tanizawa O; Minagawa J; Yamada T; Ohashi K; Ozaki M
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1799-805. PubMed ID: 4056529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gynecologic malignancies of the elderly.
    Weintraub NT; Freedman ML
    Clin Geriatr Med; 1987 Nov; 3(4):669-94. PubMed ID: 3315162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum alpha1 fetoprotein in gynecological malignancies.
    Restaino A; Sabatini R; Amoruso A; Ferreri R; Selvaggi L
    Eur J Gynaecol Oncol; 1981; 2(3):139-40. PubMed ID: 6182001
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.